Senseonics Holdings, Inc. (NASDAQ:SENS - Get Free Report) has received a consensus recommendation of "Hold" from the seven analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $14.40.
Several research firms have issued reports on SENS. HC Wainwright restated a "buy" rating and issued a $14.00 price objective on shares of Senseonics in a research note on Tuesday, November 10th. Weiss Ratings upgraded Senseonics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, November 4th. Barclays boosted their target price on Senseonics from $10.00 to $11.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 10th. Wall Street Zen raised Senseonics from a "sell" rating to a "hold" rating in a report on Saturday, November 14th. Finally, TD Cowen increased their price target on Senseonics from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Tuesday, November 10th.
View Our Latest Stock Analysis on Senseonics
Senseonics Stock Down 8.6%
Senseonics stock opened at $8.90 on Friday. The firm has a market capitalization of $487.54 million, a PE ratio of -3.87 and a beta of 1.04. The company's 50-day moving average is $9.24 and its 200-day moving average is $7.38. Senseonics has a fifty-two week low of $4.79 and a fifty-two week high of $13.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.92 and a quick ratio of 5.60.
Senseonics (NASDAQ:SENS - Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Senseonics had a negative net margin of 204.01% and a negative return on equity of 186.11%. The firm had revenue of $19.56 million during the quarter. Sell-side analysts anticipate that Senseonics will post -2.20 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Douglas Roeder acquired 17,041 shares of the firm's stock in a transaction on Friday, November 13th. The shares were purchased at an average cost of $10.32 per share, for a total transaction of $175,863.12. Following the completion of the acquisition, the director directly owned 189,712 shares in the company, valued at approximately $1,957,827.84. This trade represents a 9.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.70% of the stock is currently owned by company insiders.
Institutional Trading of Senseonics
A number of hedge funds have recently modified their holdings of SENS. Goldman Sachs Group Inc. lifted its position in Senseonics by 60.6% during the third quarter. Goldman Sachs Group Inc. now owns 371,706 shares of the company's stock worth $3,780,000 after acquiring an additional 140,197 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Senseonics during the third quarter worth approximately $621,000. Ieq Capital LLC bought a new stake in shares of Senseonics during the third quarter worth approximately $215,000. StoneX Group Inc. acquired a new position in shares of Senseonics in the third quarter valued at approximately $128,000. Finally, Traynor Capital Management Inc. acquired a new position in shares of Senseonics in the third quarter valued at approximately $152,000. Institutional investors and hedge funds own 12.36% of the company's stock.
Senseonics Company Profile
(
Get Free Report)
Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Senseonics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senseonics wasn't on the list.
While Senseonics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.